Solgama · BMJ open 2024 · ecological study · n=?

State-level variation in distribution of oxycodone and opioid-related deaths from 2000 to 2021: an ecological study of ARCOS and CDC WONDER data in the USA.

Cited 8 times in the scientific literature.

Level 4 - case-series / case-control

Ecological observational study analyzing aggregate state-level administrative and mortality data

PubMed 38453203 · doi:10.1136/bmjopen-2023-073765 · record verified 2026-08-28

What was done

This ecological observational study characterized US state-level oxycodone distribution and opioid-related mortality from 2000 to 2021. Distribution data by business type (pharmacies, hospitals, and practitioners) were obtained from Drug Enforcement Administration (DEA) ARCOS annual reports, converted to morphine milligram equivalents (MME) per capita, and normalized by population. Mortality data across specific opioid categories were retrieved from CDC WONDER.

What was found

Total oxycodone MME/person rose 280.13% from 2000 to 2010, followed by a 54.34% decline from 2010 to 2021. In the peak year (2010), a 15-fold difference existed between the highest- and lowest-distributing states. Pharmacies accounted for >94% of total MME/person distributed. Consistent, substantial elevations in combined MME/person occurred in Florida (2007–2011), Delaware (2003–2020), and Tennessee (2012–2021). Practitioner-distributed oxycodone in Florida was nearly 15-fold above the national state average from 2006 to 2010. Total opioid-related deaths rose 806% over the study period, primarily driven by heroin, other opioids, and other synthetic narcotics.

Why it matters

It maps long-term geographic and channel-specific trends in prescription opioid supply against the continuing overdose crisis, identifying states with extreme historical supply variations.

Limits

The ecological design precludes individual-level causal conclusions between supply and overdose deaths. Findings rely on administrative aggregate distribution metrics and death certificate coding without measuring illicit drug market dynamics or patient-level outcomes.

Cited by